Compare BioNTech SE - ADR (BNTX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.65 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 2× BioNTech SE - ADR's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | TTWO | |
|---|---|---|
Market Cap | $23.31B | $46.84B |
Sector | Health | Media |
52-Week High | $119.34 | $262.29 |
52-Week Low | $83.89 | $189.69 |
Enterprise Value | $6.60B | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Take-Two Interactive (TTWO) trades at $244.33, down 3.64% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by NBA 2K and Grand Theft Auto performance, while the company maintains focus on the upcoming GTA VI launch in November 2026. Fundamentals show revenue growth to $5.63B in 2025, but net losses persist, with a negative net income margin of -4.79%.
The stock's upside potential is tied to GTA VI's success, with a consensus price target of $300.55 offering 23% upside. Key risks include execution on the high-stakes game launch, sustained profitability challenges, and competitive pressures in the gaming industry. Investor sentiment remains optimistic due to the blockbuster title's preorder momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
